On July 10-12, 2021, the 3rd Global Conference on BioPharma Frontier Technology was successfully held by Tongxieyi New Drug Elite Club in Suzhou International Expo Center bordering Jinji Lake, guided by the Suzhou Industrial Park Administrative Committee, the Working Committee on Biotechnology and Pharmacy of Chinese Peasants and Workers Democratic Party, and the National Biopharmaceutical Technology Innovation Center.
Nine academicians, 150 exhibitors, 300 presentors, more than 1,000 entrepreneurs, and more than 4,000 participants were involved in this conference with one main forum and 21 sub-forums. Topics of the conference include cross-border drug business cooperation, collaborative development and investment between pharmaceutical companies and Biotech, innovative technology of new drug sources, development of complex preparations and improved new drugs, AI-enabled new drugs, and precision medicine and new drugs, innovative development of traditional Chinese medicine, innovative medical devices, pharmaceutical engineering, development of new antibody drugs, cell therapy drugs, RNA technology drugs and vaccines, and gene therapy drugs, international registration of new drugs, clinical development of new drugs, clinical development of anti-tumor drugs, project approval and development of nervous system drugs and etc., bringing a feast for the circle of pharmaceutical innovation.
Liu Shen biomedical team participated in the conference for three consecutive years and had friendly exchanges with the participants. Adhering to the concept of “serving innovation, assisting innovation”, Liu Shen has always been striving to actively promote the innovative medicine industry and the intellectual property development of China.
Participating team (from left to right): Dr. Liu Guojun, Dr. Stephen Zou, Dr. Zhang Yuan, Dr. Tu Tao
Client consultation with Dr. Stephen Zou
Dr. Liu Guojun and Dr. Tu Tao communicating with clients
Client consultation with Dr. Zhang Yuan
Introduction of the team
Life and Health Team of Liu Shen includes 28 core personnel, all of whom are qualified as patent attorneys, including 15 persons with lawyer qualification and 12 with doctoral degree, in various technical fields such as small molecule drugs, antibody drugs, CAR-T therapy, gene editing, nucleic acid vaccines/drugs. The legal team consisting of double-qualified attorneys has rich experience in handling legal affairs related to the field of One Health, extensively participating in dispute resolution, due diligence investigation of investment and financing, licensing negotiation, IPO-related IP due diligence investigation, and providing patent mapping and operating strategies for companies.